STOCK TITAN
  1. Home
  2. Sec-filings
  3. VYNE
  4. [Form 4] VYNE Therapeutics Inc. Insider Trading Activity

VYNE Therapeutics (VYNE) CEO has 79,391 shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reports that President and CEO David Domzalski had 79,391 shares of Common Stock withheld by the issuer at $0.8976 per share to satisfy tax obligations related to the vesting of restricted stock units. After this tax-withholding disposition, he directly holds 347,174 shares.

Positive

  • None.

Negative

  • None.
Insider Domzalski David
Role PRESIDENT AND CEO
Type Security Shares Price Value
Tax Withholding Common Stock F1 79,391 $0.8976 $71K
Holdings After Transaction: Common Stock — 347,174 shares (Direct)
Footnotes (1)
  1. F1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
Shares withheld for taxes 79,391 shares Common Stock withheld on 2026-07-23 to satisfy tax withholding on RSU vesting
Tax-withholding share value US$0.8976 per share Per-share value used for the 79,391-share tax-withholding disposition
Shares held after transaction 347,174 shares Common Stock directly held by CEO David Domzalski after the tax withholding
restricted stock units financial
"in connection with the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding requirements financial
"withheld by the Issuer to satisfy tax withholding requirements"
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider share event did VYNE (VYNE) report for its CEO?
VYNE Therapeutics reported that CEO David Domzalski had 79,391 Common shares withheld by the company to cover tax obligations on vested restricted stock units. This transaction is classified as a tax-withholding disposition rather than an open-market purchase or sale.

How many VYNE (VYNE) shares were withheld for CEO David Domzalski’s taxes?
A total of 79,391 VYNE Therapeutics Common shares were withheld to satisfy tax withholding requirements. The value was recorded at $0.8976 per share, and the shares relate to the vesting of previously granted restricted stock units.

How many VYNE (VYNE) shares does the CEO hold after the tax-withholding event?
After the tax-withholding disposition, CEO David Domzalski directly holds 347,174 VYNE Therapeutics Common shares. This figure reflects his direct ownership position following the withholding of 79,391 shares for tax obligations tied to restricted stock unit vesting.

Was the VYNE (VYNE) CEO tax-withholding transaction under a Rule 10b5-1 trading plan?
The transaction is not identified as being made under a Rule 10b5-1 trading plan. The company’s disclosure does not indicate that this tax-withholding disposition was executed pursuant to any pre-arranged trading arrangement for the CEO’s shares.

Did the VYNE (VYNE) CEO sell shares in the open market in this transaction?
No open-market sale is reported. The 79,391 shares were withheld by the issuer to satisfy tax withholding requirements on vested restricted stock units, meaning the shares were used to cover taxes rather than sold through market transactions.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Domzalski David
(Last)(First)(Middle)
C/O VYNE THERAPEUTICS INC.
P.O. BOX 125
(Street)
STEWARTSVILLE NEW JERSEY 08886
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT AND CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/23/2026F(1)79,391D$0.8976347,174D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.
/s/ Mutya Harsch, Attorney-in-Fact07/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR